IBD

CT-P13 biosimilar is non-inferior to infliximab

Article metrics

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original article

    1. Ye, B. D. et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet 393, 1699–1707 (2019)

    Download references

    Author information

    Correspondence to Iain Dickson.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark